Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism.

Petrou T, Olsen HL, Thrasivoulou C, Masters JR, Ashmore JF, Ahmed A.

J Pharmacol Exp Ther. 2017 Feb;360(2):378-387. doi: 10.1124/jpet.116.236695. Epub 2016 Dec 15.

2.

Quantitative Expression and Co-Localization of Wnt Signalling Related Proteins in Feline Squamous Cell Carcinoma.

Giuliano A, Swift R, Arthurs C, Marote G, Abramo F, McKay J, Thomson C, Beltran M, Millar M, Priestnall S, Dobson J, Costantino-Casas F, Petrou T, McGonnell IM, Davies AJ, Weetman M, Garden OA, Masters JR, Thrasivoulou C, Ahmed A.

PLoS One. 2016 Aug 25;11(8):e0161103. doi: 10.1371/journal.pone.0161103. eCollection 2016. Erratum in: PLoS One. 2016;11(9):e0163838.

3.

Plexin-B1 signalling promotes androgen receptor translocation to the nucleus.

Williamson M, de Winter P, Masters JR.

Oncogene. 2016 Feb 25;35(8):1066-72. doi: 10.1038/onc.2015.160. Epub 2015 May 18.

PMID:
25982277
4.

Targets of Wnt/ß-catenin transcription in penile carcinoma.

Arya M, Thrasivoulou C, Henrique R, Millar M, Hamblin R, Davda R, Aare K, Masters JR, Thomson C, Muneer A, Patel HR, Ahmed A.

PLoS One. 2015 Apr 22;10(4):e0124395. doi: 10.1371/journal.pone.0124395. eCollection 2015.

5.

Guidelines for the use of cell lines in biomedical research.

Geraghty RJ, Capes-Davis A, Davis JM, Downward J, Freshney RI, Knezevic I, Lovell-Badge R, Masters JR, Meredith J, Stacey GN, Thraves P, Vias M; Cancer Research UK.

Br J Cancer. 2014 Sep 9;111(6):1021-46. doi: 10.1038/bjc.2014.166. Epub 2014 Aug 12.

6.

Clonogenicity: holoclones and meroclones contain stem cells.

Beaver CM, Ahmed A, Masters JR.

PLoS One. 2014 Feb 26;9(2):e89834. doi: 10.1371/journal.pone.0089834. eCollection 2014.

7.

Quantitative analysis of BTF3, HINT1, NDRG1 and ODC1 protein over-expression in human prostate cancer tissue.

Symes AJ, Eilertsen M, Millar M, Nariculam J, Freeman A, Notara M, Feneley MR, Patel HR, Masters JR, Ahmed A.

PLoS One. 2013 Dec 27;8(12):e84295. doi: 10.1371/journal.pone.0084295. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/80c6bb6d-657b-46be-ba77-3de5d528c89e. Patel, Hitenedra R H [corrected to Patel, Hitendra R H].

8.

Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line.

Capes-Davis A, Alston-Roberts C, Kerrigan L, Reid YA, Barrett T, Burnett EC, Cooper JR, Freshney RI, Healy L, Kohara A, Korch C, Masters JR, Nakamura Y, Nims RW, Storts DR, Dirks WG, MacLeod RA, Drexler HG.

Genes Chromosomes Cancer. 2013 Oct;52(10):986-8. doi: 10.1002/gcc.22094. Epub 2013 Aug 1. No abstract available.

PMID:
23907998
9.

Function of mutant and wild-type plexinb1 in prostate cancer cells.

Damola A, Legendre A, Ball S, Masters JR, Williamson M.

Prostate. 2013 Sep;73(12):1326-35. doi: 10.1002/pros.22678. Epub 2013 Jun 15.

10.

Cell-line authentication: End the scandal of false cell lines.

Masters JR.

Nature. 2012 Dec 13;492(7428):186. doi: 10.1038/492186a. No abstract available.

PMID:
23235867
11.

Match criteria for human cell line authentication: where do we draw the line?

Capes-Davis A, Reid YA, Kline MC, Storts DR, Strauss E, Dirks WG, Drexler HG, MacLeod RA, Sykes G, Kohara A, Nakamura Y, Elmore E, Nims RW, Alston-Roberts C, Barallon R, Los GV, Nardone RM, Price PJ, Steuer A, Thomson J, Masters JR, Kerrigan L.

Int J Cancer. 2013 Jun 1;132(11):2510-9. doi: 10.1002/ijc.27931. Epub 2012 Nov 28.

12.

CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate.

Yamamoto H, Masters JR, Dasgupta P, Chandra A, Popert R, Freeman A, Ahmed A.

PLoS One. 2012;7(10):e46979. doi: 10.1371/journal.pone.0046979. Epub 2012 Oct 12.

13.

Effect of cancer-associated mutations in the PlexinB1 gene.

Zhou C, Wong OG, Masters JR, Williamson M.

Mol Cancer. 2012 Mar 9;11:11. doi: 10.1186/1476-4598-11-11.

14.

Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer.

Barron N, Keenan J, Gammell P, Martinez VG, Freeman A, Masters JR, Clynes M.

Prostate. 2012 Aug 1;72(11):1193-9. doi: 10.1002/pros.22469. Epub 2011 Dec 7.

PMID:
22161972
15.

Prostate cancer proteomics.

Masters JR.

OMICS. 2011 Mar;15(3):169-71. doi: 10.1089/omi.2010.0083. Epub 2011 Feb 14.

PMID:
21319990
16.

Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues.

Barallon R, Bauer SR, Butler J, Capes-Davis A, Dirks WG, Elmore E, Furtado M, Kline MC, Kohara A, Los GV, MacLeod RA, Masters JR, Nardone M, Nardone RM, Nims RW, Price PJ, Reid YA, Shewale J, Sykes G, Steuer AF, Storts DR, Thomson J, Taraporewala Z, Alston-Roberts C, Kerrigan L.

In Vitro Cell Dev Biol Anim. 2010 Oct;46(9):727-32. doi: 10.1007/s11626-010-9333-z. Epub 2010 Jul 8.

17.

A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer.

Wang Q, Symes AJ, Kane CA, Freeman A, Nariculam J, Munson P, Thrasivoulou C, Masters JR, Ahmed A.

PLoS One. 2010 May 4;5(5):e10456. doi: 10.1371/journal.pone.0010456.

18.

Detection of Mycoplasma in cell cultures.

Young L, Sung J, Stacey G, Masters JR.

Nat Protoc. 2010 May;5(5):929-34. doi: 10.1038/nprot.2010.43. Epub 2010 Apr 22.

PMID:
20431538
19.

PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion.

Wells CM, Whale AD, Parsons M, Masters JR, Jones GE.

J Cell Sci. 2010 May 15;123(Pt 10):1663-73. doi: 10.1242/jcs.055707. Epub 2010 Apr 20.

20.

Check your cultures! A list of cross-contaminated or misidentified cell lines.

Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR, Freshney RI.

Int J Cancer. 2010 Jul 1;127(1):1-8. doi: 10.1002/ijc.25242. Review.

21.

Stem cells in regenerative urology of the bladder.

Yamamoto H, Shah S, Masters JR, Popert RJ, Dasgupta P.

BJU Int. 2009 Nov;104(9):1183-4. doi: 10.1111/j.1464-410X.2009.08734.x. Epub 2009 Aug 12. No abstract available.

22.

Primary cultures of renal proximal tubule cells derived from individuals with primary hyperoxaluria.

Price KL, Hulton SA, van't Hoff WG, Masters JR, Rumsby G.

Urol Res. 2009 Jun;37(3):127-32. doi: 10.1007/s00240-009-0185-5. Epub 2009 Mar 13.

PMID:
19283374
23.

Cryopreservation and banking of mammalian cell lines.

Stacey GN, Masters JR.

Nat Protoc. 2008;3(12):1981-9. doi: 10.1038/nprot.2008.190.

PMID:
19180080
24.

False cell lines: The problem and a solution.

Masters JR.

Cytotechnology. 2002 Jul;39(2):69-74. doi: 10.1023/A:1022908930937.

25.

Prostate cancer stem cell therapy: hype or hope?

Masters JR, Kane C, Yamamoto H, Ahmed A.

Prostate Cancer Prostatic Dis. 2008;11(4):316-9. doi: 10.1038/pcan.2008.22. Epub 2008 Apr 22. Review.

PMID:
18427568
26.

A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF.

Ahmed T, Shea K, Masters JR, Jones GE, Wells CM.

Cell Signal. 2008 Jul;20(7):1320-8. doi: 10.1016/j.cellsig.2008.02.021. Epub 2008 Mar 12.

PMID:
18424072
27.

Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation.

Köberle B, Roginskaya V, Zima KS, Masters JR, Wood RD.

Mol Carcinog. 2008 Aug;47(8):580-6. doi: 10.1002/mc.20418.

PMID:
18240296
28.

Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells.

Hastie C, Masters JR, Moss SE, Naaby-Hansen S.

J Biol Chem. 2008 May 2;283(18):12595-603. doi: 10.1074/jbc.M800189200. Epub 2008 Jan 22.

29.

Allelic imbalance at 13q14.2 approximately q14.3 in localized prostate cancer is associated with early biochemical relapse.

Brookman-Amissah N, Nariculam J, Freeman A, Willamson M, Kirby RS, Masters JR, Feneley MR.

Cancer Genet Cytogenet. 2007 Dec;179(2):118-26.

PMID:
18036398
30.

Plexin-B1 mutations in prostate cancer.

Wong OG, Nitkunan T, Oinuma I, Zhou C, Blanc V, Brown RS, Bott SR, Nariculam J, Box G, Munson P, Constantinou J, Feneley MR, Klocker H, Eccles SA, Negishi M, Freeman A, Masters JR, Williamson M.

Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19040-5. Epub 2007 Nov 16.

31.

Changing medium and passaging cell lines.

Masters JR, Stacey GN.

Nat Protoc. 2007;2(9):2276-84.

PMID:
17853884
32.

Clinical applications of expression profiling and proteomics in prostate cancer.

Masters JR.

Anticancer Res. 2007 May-Jun;27(3A):1273-6. Review.

33.

Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer.

Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A, Masters JR.

Oncogene. 2007 Oct 4;26(45):6560-5. Epub 2007 May 7.

PMID:
17486081
34.

A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation.

Daly-Burns B, Alam TN, Mackay A, Clark J, Shepherd CJ, Rizzo S, Tatoud R, O'Hare MJ, Masters JR, Hudson DL.

Differentiation. 2007 Jan;75(1):35-48.

PMID:
17244020
35.

XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.

Cummings M, Higginbottom K, McGurk CJ, Wong OG, Köberle B, Oliver RT, Masters JR.

Biochem Pharmacol. 2006 Jul 14;72(2):166-75. Epub 2006 May 4.

PMID:
16756962
36.

Allelic imbalance and biochemical outcome after radical prostatectomy.

Bott SR, Masters JR, Parkinson MC, Kirby RS, Feneley M, Hooper J, Williamson M.

Prostate Cancer Prostatic Dis. 2006;9(2):160-8. Epub 2006 Mar 14.

PMID:
16534511
37.

Regulation of DNA repair gene expression in human cancer cell lines.

McGurk CJ, Cummings M, Köberle B, Hartley JA, Oliver RT, Masters JR.

J Cell Biochem. 2006 Apr 1;97(5):1121-36.

PMID:
16315315
38.

Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering.

Wells CM, Ahmed T, Masters JR, Jones GE.

Cell Motil Cytoskeleton. 2005 Nov;62(3):180-94.

PMID:
16211585
39.

Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH.

Brookman-Amissah N, Duchesnes C, Williamson MP, Wang Q, Ahmed A, Feneley MR, Mackay A, Freeman A, Fenwick K, Iravani M, Weber B, Ashworth A, Masters JR.

Prostate Cancer Prostatic Dis. 2005;8(4):335-43.

PMID:
16130014
40.

Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry.

BJU Int. 2005 Aug;96(3):303-7.

41.

Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells.

Hastie C, Saxton M, Akpan A, Cramer R, Masters JR, Naaby-Hansen S.

Oncogene. 2005 Sep 1;24(38):5905-13.

PMID:
16007208
42.

Comparison of the zones of the human prostate with the seminal vesicle: morphology, immunohistochemistry, and cell kinetics.

Laczkó I, Hudson DL, Freeman A, Feneley MR, Masters JR.

Prostate. 2005 Feb 15;62(3):260-6.

PMID:
15389778
43.

Differential expression of CD44 during human prostate epithelial cell differentiation.

Alam TN, O'Hare MJ, Laczkó I, Freeman A, Al-Beidh F, Masters JR, Hudson DL.

J Histochem Cytochem. 2004 Aug;52(8):1083-90.

PMID:
15258184
44.

Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.

Welsh C, Day R, McGurk C, Masters JR, Wood RD, Köberle B.

Int J Cancer. 2004 Jun 20;110(3):352-61.

45.

Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons.

Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R, Naaby-Hansen S.

Oncogene. 2004 Mar 4;23(9):1693-703.

PMID:
14647428
46.

Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry.

Cancer. 2003 Dec 1;98(11):2362-7.

47.

Cancer stem cells.

Masters JR, Foley CL, Bisson I, Ahmed A.

BJU Int. 2003 Nov;92(7):661-2. No abstract available.

48.

Neuroendocrine differentiation in prostate cancer: is it detectable and treatable?

Birtle AJ, Freeman A, Payne HA, Masters JR, Harland SJ.

BJU Int. 2003 Sep;92(4):490. No abstract available.

49.

Curing metastatic cancer: lessons from testicular germ-cell tumours.

Masters JR, Köberle B.

Nat Rev Cancer. 2003 Jul;3(7):517-25. Review.

PMID:
12835671
50.

Rapid identification of antisense mRNA-expressing clones using strand-specific RT-PCR.

Cummings M, McGurk C, Masters JR.

Antisense Nucleic Acid Drug Dev. 2003 Apr;13(2):115-7.

PMID:
12804038

Supplemental Content

Loading ...
Support Center